RD2RD2

RD2RD2 is an all-D-enantiomeric tandem peptide developed for the treatment of Alzheimer's disease. It is a homodimer (tandem repeat) of the RD2 peptide, which itself is a derivative of the D3 peptide identified through mirror-image phage display. RD2RD2 is designed to bind with high affinity to toxic amyloid-beta (Aβ) oligomers, which are considered the primary synaptotoxic agents in Alzheimer's pathology. By stabilizing Aβ monomers or directly disaggregating existing oligomers into non-toxic species, RD2RD2 aims to prevent neurotoxicity and cognitive decline. Due to its all-D-enantiomeric structure, the peptide is highly resistant to proteolytic degradation, enhancing its stability and potential for oral administration.